Literature DB >> 2961218

At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation.

A Zatta1, A Zanetti, E Dejana, M Prosdocimi.   

Abstract

The aim of this study was to investigate the mechanism involved in beta-thromboglobulin (BTG) release induced by platelet activating factor (PAF) in human platelet-rich plasma (PRP) and washed platelets (WP) during aggregation. PAF was used in PRP at increasing concentrations starting at its threshold concentration for irreversible aggregation (TAC: 90-150 nM). In citrated PRP, PAF induced release of BTG (80-95% of total content) and thromboxane B2 (TXB2) formation (30-40 pmol/ml). At low PAF concentrations aggregation and BTG release were blocked by apyrase (a scavenger of ADP), by ASA (an inhibitor of cyclooxygenase) and by BM 13177 (a thromboxane receptor antagonist). Higher concentrations of PAF overcame the effect of apyrase, but only induced reversible aggregation and minor release in the presence of ASA or BM 13177. In heparinized PRP, PAF induced full irreversible aggregation, but only very low BTG release (about 25% of total content) and thromboxane synthesis (2-3 pmol/ml). WP resuspended in the presence of 2 mmol/l Ca2+ seldom responded to PAF alone, as previously shown by others, but full aggregation could be induced by concomitant addition of subthreshold concentrations of PAF (25-50 nM) and epinephrine (1 microM). In these conditions average BTG release from WP was less than 20% of the amount releasable by thrombin. In contrast, when WP were resuspended in the absence of Ca2+, stimulation by PAF + EPI induced sustained BTG release (40-50% of total content) and TXB2 synthesis (15-20 pmol/ml). We conclude that at low Ca2+ concentration PAF induces BTG release mainly through thromboxane-endoperoxides formation. In contrast, when [Ca2+] is normal, PAF does not or weakly induces thromboxane formation and BTG release.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961218     DOI: 10.1007/bf01968831

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  29 in total

1.  The role of platelet-activating factor in platelet aggregation.

Authors:  M Chignard; J P Le Couedic; M Tence; B B Vargaftig; J Benveniste
Journal:  Nature       Date:  1979-06-28       Impact factor: 49.962

2.  Role of endogenous arachidonate metabolites in phospholipid-induced human platelet activation.

Authors:  D E MacIntyre; A M Shaw; W K Pollock; G Marks; J Westwick
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

3.  Letter: Aggregation of human platelets by platelet-activating factor.

Authors:  J Benveniste; J P Le Couedic; P Kamoun
Journal:  Lancet       Date:  1975-02-08       Impact factor: 79.321

4.  Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro.

Authors:  A J Marcus; L B Safier; H L Ullman; K T Wong; M J Broekman; B B Weksler; K L Kaplan
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

5.  Platelet activating factor (PAF) induced release of platelet factor 4 (PF4) in vitro and during IgE anaphylaxis in the rabbit.

Authors:  L M McManus; C A Morley; S P Levine; R N Pinckard
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

6.  Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.

Authors:  H Patscheke; K Stegmeier
Journal:  Thromb Res       Date:  1984-02-01       Impact factor: 3.944

7.  Mechanism of PAF-induced platelet aggregation in man.

Authors:  L J Küster; J Filep; J C Frölich
Journal:  Thromb Res       Date:  1986-08-15       Impact factor: 3.944

8.  Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway.

Authors:  A Sturk; G M Asyee; M C Schaap; M van Maanen; J W ten Cate
Journal:  Thromb Res       Date:  1985-11-01       Impact factor: 3.944

9.  Bovine endothelial cells in culture produce thromboxane as well as prostacyclin.

Authors:  C Ingerman-Wojenski; M J Silver; J B Smith; E Macarak
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

10.  The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxy- carbonylmethoxycoumarin) on washed human platelet aggregation induced by platelet activating factor (PAF) and epinephrine.

Authors:  A Zanetti; A Zatta; M Prosdocimi; E Dejana
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.